-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dupilumab in Atopic Keratoconjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Atopic Keratoconjunctivitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dupilumab in Atopic Keratoconjunctivitis Drug Details: Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Graft Versus Host Disease (GVHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Drugs In Development, 2023’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tunlametinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tunlametinib in Solid Tumor Drug Details: Tunlametinib (HL-085) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BX-2000 in Anesthetic Effect
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BX-2000 in Anesthetic Effect report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BX-2000 in Anesthetic Effect Drug Details:BX-2000 is under development for anaesthesia. The drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BX-1000 in Anesthetic Effect
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BX-1000 in Anesthetic Effect report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BX-1000 in Anesthetic Effect Drug Details:BX-1000 is under development for anaesthesia. The drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever)Drug Details:Vaccine is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma Drug Details: Naratuximab emtansine is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anzurstobart in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Head And Neck Cancer Squamous...